Bastiaan Jeroen van der Baan - 26 Sep 2023 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role: President, CEO & Vice Chairman, Director
Signature: /s/ Bastiaan van der Baan
Issuer symbol: LIXT
Transactions as of: 26 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 16 Oct 2023, 14:51:08 UTC
Previous filing: 07 Jul 2023
Next filing: 05 Oct 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+250,000	$0.000000	250,000	26 Sep 2023	Common	250,000	$1.95	Direct	F1
holding	LIXT	Options to Purchase Common Stock					10,000	26 Sep 2023	Common	10,000	$5.88	Direct
holding	LIXT	Options to Purchase Common Stock					25,000	26 Sep 2023	Common	25,000	$7.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Explanation of Responses: in connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested. The Compensation Committee ratified the grant effective October 11, 2023.

Content

Explanation of Responses: in connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested. The Compensation Committee ratified the grant effective October 11, 2023.